mRNA-3745 / Moderna - LARVOL DELTA

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) (clinicaltrials.gov) - P1/2 | N=45 | Recruiting | Sponsor: ModernaTX, Inc. | Trial primary completion date: Jan 2026 ➔ May 2026

Trial primary completion date • Metabolic Disorders • Pediatrics

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) (clinicaltrials.gov) - P1/2 | N=45 | Recruiting | Sponsor: ModernaTX, Inc. | N=33 ➔ 45 | Trial completion date: Oct 2025 ➔ Dec 2028 | Trial primary completion date: Oct 2024 ➔ Jan 2026

Enrollment change • Trial completion date • Trial primary completion date • Metabolic Disorders • Pediatrics

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) (clinicaltrials.gov) - P1/2 | N=33 | Recruiting | Sponsor: ModernaTX, Inc. | Phase classification: P1 ➔ P1/2 | N=18 ➔ 33 | Trial completion date: Jan 2024 ➔ Oct 2025 | Trial primary completion date: Jan 2024 ➔ Oct 2024

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Metabolic Disorders • Pediatrics

A Study of mRNA-3745 in Participants With Glycogen Storage Disease Type 1a (GSD1a) (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: ModernaTX, Inc.; Not yet recruiting ➔ Recruiting

Enrollment open • Metabolic Disorders